Seçim Kolak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Seçim Kolak has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Fatih Çölkesen
Department of Internal Medicine, Division of Clinical Immunology and Allergy, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
3 shared publications - Ferhat Sağun
Department of Internal Medicine, Division of Immunology and Allergy, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
3 shared publications - Mehmet Emin Gerek
Department of Internal Medicine, Faculty of Medicine, Necmettin Erbakan University, Konya, Türkiye
3 shared publications - Şevket Arslan
Department of Internal Medicine, Division of Clinical Immunology and Allergy, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
3 shared publications - Emrah Harman
Department of Internal Medicine, Division of Clinical Immunology and Allergy, Necmettin Erbakan University Faculty of Medicine, Konya, Türkiye
2 shared publications - Dursun Dursunoglu
PAMUKKALE UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DEPARTMENT OF CARDIOLOGY
1 shared publication
Latest Publications
- 17 June 2026
- Published by Necmettin Erbakan University in Selcuk Tip Dergisi
Elevated Baseline Systemic Inflammation Indices Predict Poor Response and Higher Relapse Risk in Chronic Spontaneous Urticaria Patients on Omalizumab
Amaç: Kronik Spontan Ürtiker (KSÜ) hastalarında Omalizumab'a altı aylık klinik yanıtı ve tedavi kesimi sonrası uzun vadeli nüks riskini öngörmede bazal Sistemik İmmün-İnflamasyon İndeksi (SIRI) ve Agregat Sistemik İnflamasyon İndeksi'nin (AISI) prediktif performansını değerlendirmektir. Gereç ve Yöntemler: Bu tek merkezli, retrospektif çalışmaya 312 KSÜ hastası dahil edildi; tedavisi kesilen 217 hasta nüks açısından takip edildi. Birincil sonlanım 6. ayda iyi tedavi yanıtı (Ürtiker Kontrol Testi [ÜKT] skoru ≥12), ikincil sonlanım tedavi kesimi sonrası nüks olarak tanımlandı. Performans ROC analizi ve lojistik regresyon ile değerlendirildi. Bulgular: Yanıt vermeyen grubun (n=38) bazal SIRI (Medyan 1.47 vs. 1.06; p<0.001) ve AISI (Medyan 452.98 vs. 306.06; p<0.001) değerleri, yanıt veren gruba (n=274) göre anlamlı olarak daha yüksekti. Yanıt vermemeyi öngörmede hem AISI (AUC=0.744) hem de SIRI (AUC=0.727) güçlü performans gösterdi. Nüks alt grubunda (n=217), nüks gelişenlerin (n=122) bazal SIRI (p=0.012) ve AISI (p=0.024) değerleri remisyonda kalanlara (n=95) göre anlamlı düzeyde yüksekti. Sonuç: Bazal SIRI ve AISI değerleri, KSÜ hastalarında Omalizumab'a yetersiz yanıtı ve nüks riskini öngörmede değerli, pratik ve uygun maliyetli biyobelirteçlerdir. Bu indeksler, tedavi kararlarına rehberlik etmede ve hasta yönetimini optimize etmede klinisyenlere yardımcı olabilir.
- 17 June 2026
- Published by Necmettin Erbakan University in Selcuk Tip Dergisi
Elevated Baseline Systemic Inflammation Indices Predict Poor Response and Higher Relapse Risk in Chronic Spontaneous Urticaria Patients on Omalizumab
Amaç: Kronik Spontan Ürtiker (KSÜ) hastalarında Omalizumab'a altı aylık klinik yanıtı ve tedavi kesimi sonrası uzun vadeli nüks riskini öngörmede bazal Sistemik İmmün-İnflamasyon İndeksi (SIRI) ve Agregat Sistemik İnflamasyon İndeksi'nin (AISI) prediktif performansını değerlendirmektir. Gereç ve Yöntemler: Bu tek merkezli, retrospektif çalışmaya 312 KSÜ hastası dahil edildi; tedavisi kesilen 217 hasta nüks açısından takip edildi. Birincil sonlanım 6. ayda iyi tedavi yanıtı (Ürtiker Kontrol Testi [ÜKT] skoru ≥12), ikincil sonlanım tedavi kesimi sonrası nüks olarak tanımlandı. Performans ROC analizi ve lojistik regresyon ile değerlendirildi. Bulgular: Yanıt vermeyen grubun (n=38) bazal SIRI (Medyan 1.47 vs. 1.06; p<0.001) ve AISI (Medyan 452.98 vs. 306.06; p<0.001) değerleri, yanıt veren gruba (n=274) göre anlamlı olarak daha yüksekti. Yanıt vermemeyi öngörmede hem AISI (AUC=0.744) hem de SIRI (AUC=0.727) güçlü performans gösterdi. Nüks alt grubunda (n=217), nüks gelişenlerin (n=122) bazal SIRI (p=0.012) ve AISI (p=0.024) değerleri remisyonda kalanlara (n=95) göre anlamlı düzeyde yüksekti. Sonuç: Bazal SIRI ve AISI değerleri, KSÜ hastalarında Omalizumab'a yetersiz yanıtı ve nüks riskini öngörmede değerli, pratik ve uygun maliyetli biyobelirteçlerdir. Bu indeksler, tedavi kararlarına rehberlik etmede ve hasta yönetimini optimize etmede klinisyenlere yardımcı olabilir.
- Open Access
- 1 January 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (1) , 72-78
The relationship between neutropenia and disease prognosis in patients with Common Variable Immunodeficiency (CVID)
Objective: This study aimed to determine the frequency of neutropenia in patients with common variable immunodeficiency (CVID) and investigate its relationship with disease prognosis. Methods: Data from 84 patients diagnosed with CVID and followed between 2019 and 2024 at the Department of Adult Clinical Immunology and Allergy, Necmettin Erbakan University, were retrospectively reviewed. Patients were divided into two groups based on the presence or absence of neutropenia. Demographic data, clinical findings, laboratory parameters, and survival rates were compared. Statistical analyses included the Mann–Whitney U test, the Chi-square test, and the Kaplan–Meier survival analysis. Results: A total of 84 patients diagnosed with CVID were included in the study, with a median age of 38 years (range, 20–79 years). Of the participants, 48.8% were females (n = 41). Neutropenia was observed in 28.5% of patients (n = 24). The most common presenting complaints included autoimmune cytopenias, such as anemia and thrombocytopenia. Compared to non-neutropenic patients (n = 60), those with neutropenic CVID had a significantly higher mortality rate (33.3% vs 6.7%, P = 0.004). According to Kaplan–Meier survival analysis, the 8-year survival rates were 57.5 and 92.5% for neutropenic and for non-neutropenic CVID patients (p < 0.001), respectively. Conclusion: This study suggests that neutropenia in CVID patients may be more than just a hematological issue; it could also serve as an important clinical marker associated with increased mortality. Recognizing and closely monitoring neutropenia is essential for effective CVID management.
- 1 January 2026
- Published by Codon Publications in Allergologia et Immunopathologia
- Vol. 54 (1) , 72-78
Open AccessThe relationship between neutropenia and disease prognosis in patients with Common Variable Immunodeficiency (CVID)
Objective: This study aimed to determine the frequency of neutropenia in patients with common variable immunodeficiency (CVID) and investigate its relationship with disease prognosis. Methods: Data from 84 patients diagnosed with CVID and followed between 2019 and 2024 at the Department of Adult Clinical Immunology and Allergy, Necmettin Erbakan University, were retrospectively reviewed. Patients were divided into two groups based on the presence or absence of neutropenia. Demographic data, clinical findings, laboratory parameters, and survival rates were compared. Statistical analyses included the Mann–Whitney U test, the Chi-square test, and the Kaplan–Meier survival analysis. Results: A total of 84 patients diagnosed with CVID were included in the study, with a median age of 38 years (range, 20–79 years). Of the participants, 48.8% were females (n = 41). Neutropenia was observed in 28.5% of patients (n = 24). The most common presenting complaints included autoimmune cytopenias, such as anemia and thrombocytopenia. Compared to non-neutropenic patients (n = 60), those with neutropenic CVID had a significantly higher mortality rate (33.3% vs 6.7%, P = 0.004). According to Kaplan–Meier survival analysis, the 8-year survival rates were 57.5 and 92.5% for neutropenic and for non-neutropenic CVID patients (p < 0.001), respectively. Conclusion: This study suggests that neutropenia in CVID patients may be more than just a hematological issue; it could also serve as an important clinical marker associated with increased mortality. Recognizing and closely monitoring neutropenia is essential for effective CVID management.
- 26 September 2025
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 47 (6) , 939-950
Incidence and Risk Factors of Chronic Thromboembolic Pulmonary Hypertension Following Acute Pulmonary Embolism
This study aimed to determine the incidence of chronic thromboembolic pulmonary hypertension (CTEPH) following acute pulmonary embolism (PE) and to identify associated risk factors. A total of 256 adult patients diagnosed with acute PE in 2018 and 2019 at a tertiary care center were retrospectively evaluated. Diagnostic and follow-up procedures included clinical scoring, echocardiography, computed tomography pulmonary angiography (CTPA), and/or ventilation/perfusion (V/Q) scintigraphy. To assess the development of CTEPH, we analyzed baseline characteristics and follow-up data for each cohort over a two-year period: 2018 to 2020 for patients diagnosed in 2018, and 2019 to 2021 for those diagnosed in 2019. Right heart catheterization (RHC) findings and follow-up imaging at the third and sixth months were reviewed. Demographic, clinical, laboratory, and radiological variables were compared between patients with and without CTEPH. The incidence of CTEPH was 7.8% (n=20). Right ventricular (RV) dilatation at initial imaging was significantly more frequent in the CTEPH group (p=0.042). At both the third and sixth months, elevated systolic pulmonary artery pressure (sPAP) >50 mmHg, tricuspid regurgitation (TR), and tricuspid regurgitation velocity (TRV) >2.8 m/s were significantly more common in CTEPH patients (p<0.05). No significant association was found with genetic thrombophilia, whereas antiphospholipid antibodies and lupus anticoagulant were more prevalent but not statistically significant. Although rare, CTEPH is associated with high morbidity and mortality but remains potentially curable if diagnosed early. Early signs such as RV dysfunction may help identify high-risk patients. Therefore, structured follow-up protocols are essential to ensure timely diagnosis and referral to specialized centers.
- 26 September 2025
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 47 (6) , 939-950
Incidence and Risk Factors of Chronic Thromboembolic Pulmonary Hypertension Following Acute Pulmonary Embolism
This study aimed to determine the incidence of chronic thromboembolic pulmonary hypertension (CTEPH) following acute pulmonary embolism (PE) and to identify associated risk factors. A total of 256 adult patients diagnosed with acute PE in 2018 and 2019 at a tertiary care center were retrospectively evaluated. Diagnostic and follow-up procedures included clinical scoring, echocardiography, computed tomography pulmonary angiography (CTPA), and/or ventilation/perfusion (V/Q) scintigraphy. To assess the development of CTEPH, we analyzed baseline characteristics and follow-up data for each cohort over a two-year period: 2018 to 2020 for patients diagnosed in 2018, and 2019 to 2021 for those diagnosed in 2019. Right heart catheterization (RHC) findings and follow-up imaging at the third and sixth months were reviewed. Demographic, clinical, laboratory, and radiological variables were compared between patients with and without CTEPH. The incidence of CTEPH was 7.8% (n=20). Right ventricular (RV) dilatation at initial imaging was significantly more frequent in the CTEPH group (p=0.042). At both the third and sixth months, elevated systolic pulmonary artery pressure (sPAP) >50 mmHg, tricuspid regurgitation (TR), and tricuspid regurgitation velocity (TRV) >2.8 m/s were significantly more common in CTEPH patients (p<0.05). No significant association was found with genetic thrombophilia, whereas antiphospholipid antibodies and lupus anticoagulant were more prevalent but not statistically significant. Although rare, CTEPH is associated with high morbidity and mortality but remains potentially curable if diagnosed early. Early signs such as RV dysfunction may help identify high-risk patients. Therefore, structured follow-up protocols are essential to ensure timely diagnosis and referral to specialized centers.
- Open Access
- 24 September 2025
- Published by Springer Nature in BMC Immunology
- Vol. 26 (1) , 1-12
Autoimmune cytopenias in inborn errors of immunity: associations with monogenic mutations and immunologic parameters
Background: Autoimmune cytopenias (AICs) are among the most frequent non-infectious complications in inborn errors of immunity (IEIs) and may represent early or even initial manifestations. The genetic underpinnings of AICs in IEIs remain heterogeneous and incompletely defined. Objective: This study aimed to determine the prevalence and distribution of AICs and to investigate their associations with underlying monogenic mutations and selected immunophenotypic parameters in adult patients with IEI. Methods: A total of 121 adult IEI patients from a single tertiary immunology center were evaluated retrospectively. Clinical, immunophenotypic, and genetic data were obtained from electronic medical records. Comparisons were made between patients with and without autoimmune manifestations and AICs. Monogenic mutations were identified using targeted next-generation sequencing (NGS). Results: Autoimmune manifestations were present in 48 of 121 patients (39.6%), and autoimmune cytopenias (AICs) were identified in 33 patients (27.5%). Autoimmune hemolytic anemia (AIHA) was the most frequently observed subtype, followed by combined cytopenias and immune thrombocytopenia (ITP). The most common genetic alteration detected was a mutation in TNFRSF13B (TACI), with additional variants identified in DOCK8, RAG1, LRBA, PRF1, PSTPIP1, CECR1, PRKDC, and MRTFA. Logistic regression revealed a strong independent association between TACI mutations and ITP (OR: 46.5, p = 0.002), while no significant relationship was found with autoimmune cytopenias overall. No statistically significant differences were found in class-switched memory B cells (CD27⁺IgD⁻) percentages, CD4⁺/CD8⁺ T-cell ratios, or baseline IgG concentrations between patients with and without autoimmune manifestations or AICs. Conclusion: AICs represent a significant clinical burden in adult IEIs and may occur in association with a wide range of genetic variants. Class-switched memory B cells (CD27⁺IgD⁻) percentages, CD4⁺/CD8⁺ T-cell ratio, and baseline IgG were not significantly associated with autoimmunity in this cohort. These findings underscore the need for broader immunophenotypic and genetic screening to improve the early recognition and management of autoimmune complications in IEIs.
- 24 September 2025
- Published by Springer Nature in BMC Immunology
- Vol. 26 (1) , 1-12
Open AccessAutoimmune cytopenias in inborn errors of immunity: associations with monogenic mutations and immunologic parameters
Background: Autoimmune cytopenias (AICs) are among the most frequent non-infectious complications in inborn errors of immunity (IEIs) and may represent early or even initial manifestations. The genetic underpinnings of AICs in IEIs remain heterogeneous and incompletely defined. Objective: This study aimed to determine the prevalence and distribution of AICs and to investigate their associations with underlying monogenic mutations and selected immunophenotypic parameters in adult patients with IEI. Methods: A total of 121 adult IEI patients from a single tertiary immunology center were evaluated retrospectively. Clinical, immunophenotypic, and genetic data were obtained from electronic medical records. Comparisons were made between patients with and without autoimmune manifestations and AICs. Monogenic mutations were identified using targeted next-generation sequencing (NGS). Results: Autoimmune manifestations were present in 48 of 121 patients (39.6%), and autoimmune cytopenias (AICs) were identified in 33 patients (27.5%). Autoimmune hemolytic anemia (AIHA) was the most frequently observed subtype, followed by combined cytopenias and immune thrombocytopenia (ITP). The most common genetic alteration detected was a mutation in TNFRSF13B (TACI), with additional variants identified in DOCK8, RAG1, LRBA, PRF1, PSTPIP1, CECR1, PRKDC, and MRTFA. Logistic regression revealed a strong independent association between TACI mutations and ITP (OR: 46.5, p = 0.002), while no significant relationship was found with autoimmune cytopenias overall. No statistically significant differences were found in class-switched memory B cells (CD27⁺IgD⁻) percentages, CD4⁺/CD8⁺ T-cell ratios, or baseline IgG concentrations between patients with and without autoimmune manifestations or AICs. Conclusion: AICs represent a significant clinical burden in adult IEIs and may occur in association with a wide range of genetic variants. Class-switched memory B cells (CD27⁺IgD⁻) percentages, CD4⁺/CD8⁺ T-cell ratio, and baseline IgG were not significantly associated with autoimmunity in this cohort. These findings underscore the need for broader immunophenotypic and genetic screening to improve the early recognition and management of autoimmune complications in IEIs.